

Board of Directors – 2025 Operational Summary

Date	Discussion Item	Resolutions
2025/03/05	<ul style="list-style-type: none"> • The Company's 2024 Statement on Internal Control • Evaluation on the Company CPA's independence and competency • 2024 Business Operation Report and Financial Statements • 2024 Surplus Distribution in the form of Cash Dividend • Distribute new shares for capital increase by earnings • Proposal to issue restricted shares awards plan • Status for the Company's treasury stock • Status for the Company's 3rd domestic unsecured convertible corporate bonds and 1st oversea unsecured zero coupon euro convertible bonds • To revise the Articles of Incorporation • To revise the Internal Control Self-Assessment Procedure • To revise the Corporate Governance Best Practice Principles and Personal Information Protection Policy • Proposal to discharge the Company's manager's non compete clause • The Company's Board of Director's resolution on 2025 stockholder meeting and related item • Propose to sign loan agreement with financial institution • Proposal to formulate the record date of cash capital increase for the Company's 2020 and 2022 employee stock option exercised and the Company's 3rd domestic unsecured convertible corporate bonds • 2024 employees' and directors' compensation • 2024 directors compensation distribution detail • 2024 manager's performance result and employee remuneration distribution detail • 2024 directors compensation distribution detail for the Company's subsidiary Twi Pharmaceuticals, Inc. • The Company's 2025 managerial personnel remuneration raise • Proposal to issue the Company's 2024 first employee stock options to non-manager 	Unanimously approved by all attending members without objection

	<ul style="list-style-type: none"> Transfer the treasury stock to non-manager in accordance to “2022 Stock Repurchase and Transfer to Employee Program” 	
2025/04/08	<ul style="list-style-type: none"> To revise the Company’s “2022 Stock Repurchase and Transfer to Employee Program” To buyback the Company’s shares 	Unanimously approved by all attending members without objection
2025/05/14	<ul style="list-style-type: none"> Proposal for the company’s consolidated financial report for the first quarter of 2025 Proposal to formulate the record date of cash capital increase for the Company’s 2020 and 2022 employee stock option exercised and the Company’s 3nd domestic unsecured convertible corporate bonds Proposal to sign loan agreement with financial institution Proposal to authorize the chairman to handle the operating asset transfer and partial asset disposal of the 100% material subsidiary Upsher-Smith Proposal to provide a loan guarantee amounted to USD 20 million to subsidiary Bora Pharmaceuticals Inc. Proposal to provide a loan guarantee amounted to USD 70 million to subsidiary Upsher-Smith Laboratories, LLC Proposal for the Company’s 100% owned subsidiary Bora Pharmaceuticals Injectables Inc. to purchase the operating asset To revise the Sustainable Development Best Practice Principles The Company 2024 ESG material topic, management, and sustainability report Proposal for the Company’s subsidiary Twi Pharmaceuticals, Inc. to repurchase its 2022 issued employee stock option Transfer the treasury stock to non-manager in accordance to “2022 Stock Repurchase and Transfer to Employee Program” 	Unanimously approved by all attending members without objection
2025/5/23	<ul style="list-style-type: none"> To authorize the Company’s Board of Director’s resolution on ex-rights date and the price adjustment for the employee stock option and the Company’s 3nd domestic unsecured convertible corporate bonds Proposal to participate the cash capital increase of the Company’s investment company Tanvex BioPharma, Inc. 	Unanimously approved by all attending members without objection

	<ul style="list-style-type: none"> • Proposal to provide a loan guarantee amounted to USD 15 million to subsidiary Bora Pharmaceuticals Injectables Inc. • To revise the terms and conditions for the Company's 3rd domestic unsecured convertible corporate bonds • To revise the terms and conditions for the Company's 1st oversea unsecured zero coupon euro convertible bonds 	
2025/06/13	<ul style="list-style-type: none"> • Proposal for the Company to participate the cash capital increase to Bora Pharmaceutical and Consumer Health Inc. • Proposal for the Company's subsidiary Twi Pharmaceuticals, Inc. to sell two R&D project • Proposal to sign loan agreement with financial institution • Transfer the treasury stock to non-manager in accordance to "2022 Stock Repurchase and Transfer to Employee Program" 	Unanimously approved by all attending members without objection
2025/08/08	<ul style="list-style-type: none"> • Proposal for the company's consolidated financial report for the second quarter of 2025 • Proposal to distribute the Company's earnings for the first half of 2025 • Proposal to formulate the record date of cash capital increase for the Company's 2020 and 2022 employee stock option exercised and the Company's 3rd domestic unsecured convertible corporate bonds • Proposal for the Company to participate the cash capital increase of USD \$40,000 to Bora Global Ltd., a newly established 100% owned subsidiary in the British Virgin Islands • Proposal to sign loan agreement with financial institution • Proposal to revise the Company's 2025 restricted shares awards plan • Proposal to issue the employee stock option • Proposal to set managerial ESG performance-linked compensation indicators • Proposal to appoint Mark Kang, the Company's senior finance manager, as the Company's manager • Proposal to issue the Company's 2024 first employee stock options to manager • Proposal to issue the Company's 2025 restricted shares awards plan to manager • Transfer the treasury stock to non-manager in accordance to "2022 Stock Repurchase and Transfer to Employee Program" 	Unanimously approved by all attending members without objection

	<ul style="list-style-type: none"> · Proposal to issue the Company's 2024 first employee stock options to non-manager · Proposal to issue the Company's 2025 restricted shares awards plan to non-manager 	
2025/10/13	<ul style="list-style-type: none"> · Proposal for the Company to participate the overseas depository receipts in the U.S. over-the-counter market with its already issued shares. · Proposal to sign loan agreement with financial institution 	Unanimously approved by all attending members without objection
2025/11/13	<ul style="list-style-type: none"> · Proposal for the company's consolidated financial report for the third quarter of 2025 · Proposal to issue the Company's 4th and 5th domestic unsecured convertible corporate bonds · Proposal to sign loan agreement with financial institution · Proposal to discharge the Company's manager's non compete clause · To revise the Management Measures for the Reporting and Appeal System · To set the ESG short, mid and long term goal for 2025 · Proposal to engage Crowe (TW) CPAs to provide assurance on the greenhouse inventory and · TUV Rheinland on the assurance for the 2024 Sustainability Report · To establish the related operating procedures for the Company's sustainable development. · Proposal to appoint Nadiya Chen as the sustainable development committee member · To buyback the Company's shares 	Unanimously approved by all attending members without objection
2025/12/04	<ul style="list-style-type: none"> · Proposal to set the capital increase base date for the issuance of new shares related to the 2025 exercise of employee stock options granted in 2020, 2022 and 2023 and the conversion of the third domestic unsecured convertible bonds into new shares 	Unanimously approved by all attending members without objection
2025/12/16	<ul style="list-style-type: none"> · The Company's 2026 operating plan · The Company's 2026 budget · The Company's 2026 internal audit plan · Amendment on the internal control system · To define the scope of the Company's junior colleague · To revise the Company's 2025 first employee stock options · Propose to sign loan agreement with financial institution 	Unanimously approved by all attending members without objection



	<ul style="list-style-type: none">· Promotion for the Company's accounting manager· The Company's 2025 year end bonus for manager· Transfer the treasury stock to manager in accordance to "2022 Stock Repurchase and Transfer to Employee Program"· Transfer the treasury stock to non-manager in accordance to "2022 Stock Repurchase and Transfer to Employee Program"	
--	--	--